147 related articles for article (PubMed ID: 12841872)
1. Identification of a prostate-specific membrane antigen-derived peptide capable of eliciting both cellular and humoral immune responses in HLA-A24+ prostate cancer patients.
Kobayashi K; Noguchi M; Itoh K; Harada M
Cancer Sci; 2003 Jul; 94(7):622-7. PubMed ID: 12841872
[TBL] [Abstract][Full Text] [Related]
2. Prostate-specific antigen-derived epitopes capable of inducing cellular and humoral responses in HLA-A24+ prostate cancer patients.
Harada M; Kobayashi K; Matsueda S; Nakagawa M; Noguchi M; Itoh K
Prostate; 2003 Oct; 57(2):152-9. PubMed ID: 12949939
[TBL] [Abstract][Full Text] [Related]
3. Screening of HLA-A24-restricted epitope peptides from prostate-specific membrane antigen that induce specific antitumor cytotoxic T lymphocytes.
Horiguchi Y; Nukaya I; Okazawa K; Kawashima I; Fikes J; Sette A; Tachibana M; Takesako K; Murai M
Clin Cancer Res; 2002 Dec; 8(12):3885-92. PubMed ID: 12473604
[TBL] [Abstract][Full Text] [Related]
4. Identification of parathyroid hormone-related protein-derived peptides immunogenic in human histocompatibility leukocyte antigen-A24+ prostate cancer patients.
Yao A; Harada M; Matsueda S; Ishihara Y; Shomura H; Noguchi M; Matsuoka K; Hara I; Kamidono S; Itoh K
Br J Cancer; 2004 Jul; 91(2):287-96. PubMed ID: 15199397
[TBL] [Abstract][Full Text] [Related]
5. DNA fusion gene vaccines induce cytotoxic T-cell attack on naturally processed peptides of human prostate-specific membrane antigen.
Vittes GE; Harden EL; Ottensmeier CH; Rice J; Stevenson FK
Eur J Immunol; 2011 Aug; 41(8):2447-56. PubMed ID: 21604260
[TBL] [Abstract][Full Text] [Related]
6. A prostate stem cell antigen-derived peptide immunogenic in HLA-A24- prostate cancer patients.
Matsueda S; Yao A; Ishihara Y; Ogata R; Noguchi M; Itoh K; Harada M
Prostate; 2004 Aug; 60(3):205-13. PubMed ID: 15176050
[TBL] [Abstract][Full Text] [Related]
7. Prostate-related antigen-derived new peptides having the capacity of inducing prostate cancer-reactive CTLs in HLA-A2+ prostate cancer patients.
Harada M; Matsueda S; Yao A; Ogata R; Noguchi M; Itoh K
Oncol Rep; 2004 Sep; 12(3):601-7. PubMed ID: 15289844
[TBL] [Abstract][Full Text] [Related]
8. Identification of a SART-1-derived peptide capable of inducing HLA-A24-restricted and tumor-specific cytotoxic T lymphocytes.
Kikuchi M; Nakao M; Inoue Y; Matsunaga K; Shichijo S; Yamana H; Itoh K
Int J Cancer; 1999 May; 81(3):459-66. PubMed ID: 10209962
[TBL] [Abstract][Full Text] [Related]
9. Identification of new prostate stem cell antigen-derived peptides immunogenic in HLA-A2(+) patients with hormone-refractory prostate cancer.
Matsueda S; Kobayashi K; Nonaka Y; Noguchi M; Itoh K; Harada M
Cancer Immunol Immunother; 2004 Jun; 53(6):479-89. PubMed ID: 14634796
[TBL] [Abstract][Full Text] [Related]
10. An HLA-A3-binding prostate acid phosphatase-derived peptide can induce CTLs restricted to HLA-A2 and -A24 alleles.
Terasaki Y; Shichijo S; Niu Y; Komatsu N; Noguchi M; Todo S; Itoh K
Cancer Immunol Immunother; 2009 Nov; 58(11):1877-85. PubMed ID: 19330328
[TBL] [Abstract][Full Text] [Related]
11. Identification of peptide vaccine candidates for prostate cancer patients with HLA-A3 supertype alleles.
Matsueda S; Takedatsu H; Yao A; Tanaka M; Noguchi M; Itoh K; Harada M
Clin Cancer Res; 2005 Oct; 11(19 Pt 1):6933-43. PubMed ID: 16203785
[TBL] [Abstract][Full Text] [Related]
12. Identification of HER2/ neu-derived peptides capable of inducing both cellular and humoral immune responses in HLA-A24 positive breast cancer patients.
Azuma K; Shichijo S; Shomura H; Matsueda S; Fujii T; Itoh K
Breast Cancer Res Treat; 2004 Jul; 86(1):19-29. PubMed ID: 15218358
[TBL] [Abstract][Full Text] [Related]
13. Identification of HLA-A24 epitope peptides of carcinoembryonic antigen which induce tumor-reactive cytotoxic T lymphocyte.
Nukaya I; Yasumoto M; Iwasaki T; Ideno M; Sette A; Celis E; Takesako K; Kato I
Int J Cancer; 1999 Jan; 80(1):92-7. PubMed ID: 9935237
[TBL] [Abstract][Full Text] [Related]
14. HLA class I-restricted lysis of leukemia cells by a CD8(+) cytotoxic T-lymphocyte clone specific for WT1 peptide.
Ohminami H; Yasukawa M; Fujita S
Blood; 2000 Jan; 95(1):286-93. PubMed ID: 10607714
[TBL] [Abstract][Full Text] [Related]
15. Capability of SART3(109-118) peptide to induce cytotoxic T lymphocytes from prostate cancer patients with HLA class I-A11, -A31 and -A33 alleles.
Mohamed ER; Naito M; Terasaki Y; Niu Y; Gohara S; Komatsu N; Shichijo S; Itoh K; Noguchi M
Int J Oncol; 2009 Feb; 34(2):529-36. PubMed ID: 19148489
[TBL] [Abstract][Full Text] [Related]
16. Host-oriented peptide evaluation using whole blood assay for generating antigen-specific cytotoxic T lymphocytes.
Kawabuchi Y; Yamaguchi Y; Ohshita A; Minami K; Toge T
Anticancer Res; 2004; 24(2C):1193-200. PubMed ID: 15154646
[TBL] [Abstract][Full Text] [Related]
17. Induction of antitumor cytotoxic T lymphocytes with a MAGE-3-encoded synthetic peptide presented by human leukocytes antigen-A24.
Tanaka F; Fujie T; Tahara K; Mori M; Takesako K; Sette A; Celis E; Akiyoshi T
Cancer Res; 1997 Oct; 57(20):4465-8. PubMed ID: 9377553
[TBL] [Abstract][Full Text] [Related]
18. Identification of HLA-A24-restricted CTL epitope from cancer-testis antigen, NY-ESO-1, and induction of a specific antitumor immune response.
Yamaguchi H; Tanaka F; Ohta M; Inoue H; Mori M
Clin Cancer Res; 2004 Feb; 10(3):890-6. PubMed ID: 14871964
[TBL] [Abstract][Full Text] [Related]
19. Aberrant expression and potency as a cancer immunotherapy target of alpha-methylacyl-coenzyme A racemase in prostate cancer.
Honma I; Torigoe T; Hirohashi Y; Kitamura H; Sato E; Masumori N; Tamura Y; Tsukamoto T; Sato N
J Transl Med; 2009 Dec; 7():103. PubMed ID: 20003233
[TBL] [Abstract][Full Text] [Related]
20. Identification of polycomb group protein enhancer of zeste homolog 2 (EZH2)-derived peptides immunogenic in HLA-A24+ prostate cancer patients.
Ogata R; Matsueda S; Yao A; Noguchi M; Itoh K; Harada M
Prostate; 2004 Sep; 60(4):273-81. PubMed ID: 15264237
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
